1719 selected records with a cited source date in 2026, shown 200 per page, newest first. This archive is selective and does not imply continuous monitoring or complete historical coverage.
PubMed lists PMID 42233554 in Journal of the American College of Cardiology as Journal Article, with publication-date metadata of 2026-06-02 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained PubMed bibliographic metadata for PMID 39864410 at 2026-07-30T16:14:08.934Z. PubMed recorded a metadata revision date of 2026-06-03 and an Entrez history date of 2025-01-26. PeptideScanner associated this retained record with the identity slug vosoritide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT07204249 at 2026-07-30T16:19:03.057Z. Its registry update date was 2026-06-03, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07614438 at 2026-11-15T22:08:31.832Z. Its registry update date was 2026-06-02, and PeptideScanner's reviewed identity mapping was vasopressin.
DailyMed lists Structured Product Labeling version 1 for the reviewed Insulin glargine-aldy label family with a published date of 2026-06-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained PubMed bibliographic metadata for PMID 42153537 at 2026-07-30T16:14:16.751Z. PubMed recorded a metadata revision date of 2026-06-02 and an Entrez history date of 2026-05-19. PeptideScanner associated this retained record with the identity slug mots-c. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT06571383 at 2026-07-30T16:19:03.050Z. Its registry update date was 2026-06-02, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06161584 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-06-01, and PeptideScanner's reviewed identity mapping was pegcetacoplan.
PeptideScanner retained ClinicalTrials.gov record NCT06482112 at 2026-11-16T17:46:45.897Z. Its registry update date was 2026-06-01, and PeptideScanner's reviewed identity mapping was efinopegdutide.
DailyMed lists Structured Product Labeling version 39 for the reviewed Linaclotide label family with a published date of 2026-06-01. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PubMed lists PMID 40914786 in Drug delivery and translational research as Journal Article, Review, with publication-date metadata of 2025-09-06 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 42043833 in JAMA internal medicine as Journal Article, with publication-date metadata of 2026-06-01 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained PubMed bibliographic metadata for PMID 38990651 at 2026-07-30T16:14:08.785Z. PubMed recorded a metadata revision date of 2026-06-01 and an Entrez history date of 2024-07-11. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 38877681 at 2026-07-30T16:20:38.897Z. PubMed recorded a metadata revision date of 2026-05-31 and an Entrez history date of 2024-06-15. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 39407425 at 2026-07-30T16:20:39.038Z. PubMed recorded a metadata revision date of 2026-05-31 and an Entrez history date of 2024-10-16. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.
FDA's public page describes agency concerns and actions involving unapproved versions of semaglutide and tirzepatide, with adverse-event information dated May 31, 2026.
PeptideScanner retained PubMed bibliographic metadata for PMID 42175654 at 2026-07-30T16:20:45.825Z. PubMed recorded a metadata revision date of 2026-05-30 and an Entrez history date of 2026-05-23. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 42217255 at 2026-07-30T16:20:46.631Z. PubMed recorded a metadata revision date of 2026-05-30 and an Entrez history date of 2026-05-30. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT03290950 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-05-29, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained PubMed bibliographic metadata for PMID 42198317 at 2026-07-30T16:20:45.939Z. PubMed recorded a metadata revision date of 2026-05-29 and an Entrez history date of 2026-05-27. PeptideScanner associated this retained record with the identity slug bpc-157. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT07610174 at 2026-07-30T16:19:36.923Z. Its registry update date was 2026-05-29, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT05774756 at 2026-07-30T16:19:36.905Z. Its registry update date was 2026-05-29, and PeptideScanner's reviewed identity mapping was setmelanotide.
PubMed lists PMID 40657227 in Indian journal of orthopaedics as Journal Article, with publication-date metadata of 2025-05-27 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained PubMed bibliographic metadata for PMID 42127399 at 2026-07-30T16:20:45.678Z. PubMed recorded a metadata revision date of 2026-05-28 and an Entrez history date of 2026-05-13. PeptideScanner associated this retained record with the identity slug dulaglutide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT06485089 at 2026-07-30T16:19:36.906Z. Its registry update date was 2026-05-28, and PeptideScanner's reviewed identity mapping was tirzepatide.
FDA's dated enforcement report D-0541-2026 lists Class II and source status Ongoing for Lupin Pharmaceuticals Inc. PeptideScanner connects the report to reviewed application ANDA215421 through exact openFDA application-number annotations.
PeptideScanner retained ClinicalTrials.gov record NCT07469800 at 2026-07-30T16:19:36.903Z. Its registry update date was 2026-05-27, and PeptideScanner's reviewed identity mapping was mazdutide.
PeptideScanner retained ClinicalTrials.gov record NCT04126070 at 2026-07-30T16:19:36.912Z. Its registry update date was 2026-05-27, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT05333003 at 2026-07-30T16:19:36.906Z. Its registry update date was 2026-05-27, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06704763 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-05-26, and PeptideScanner's reviewed identity mapping was orforglipron.
PubMed lists PMID 38253036 in American journal of nephrology as Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-01-22 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained PubMed bibliographic metadata for PMID 42189020 at 2026-07-30T16:20:45.877Z. PubMed recorded a metadata revision date of 2026-05-26 and an Entrez history date of 2026-05-26. PeptideScanner associated this retained record with the identity slug ziconotide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 39043357 at 2026-07-30T16:20:38.933Z. PubMed recorded a metadata revision date of 2026-05-24 and an Entrez history date of 2024-07-23. PeptideScanner associated this retained record with the identity slug ipamorelin. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 39793696 at 2026-07-30T16:20:39.143Z. PubMed recorded a metadata revision date of 2026-05-24 and an Entrez history date of 2025-01-10. PeptideScanner associated this retained record with the identity slug bremelanotide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT06186622 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-05-22, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT06337838 at 2026-11-16T01:33:21.554Z. Its registry update date was 2026-05-22, and PeptideScanner's reviewed identity mapping was desmopressin.
The Federal Register published notice 2026-10277, attributed to FDA and its parent HHS department, on 2026-05-22. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Palopegteriparatide.
PubMed lists PMID 40436723 in Cardiovascular revascularization medicine : including molecular interventions as Journal Article, Comparative Study, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2025-05-10 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
DailyMed lists Structured Product Labeling version 18 for the reviewed Semaglutide label family with a published date of 2026-05-22. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained PubMed bibliographic metadata for PMID 42043535 at 2026-07-30T16:20:43.712Z. PubMed recorded a metadata revision date of 2026-05-22 and an Entrez history date of 2026-04-27. PeptideScanner associated this retained record with the identity slug vosoritide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 41056349 at 2026-07-30T16:20:41.592Z. PubMed recorded a metadata revision date of 2026-05-22 and an Entrez history date of 2025-10-07. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT07605247 at 2026-07-30T16:19:36.902Z. Its registry update date was 2026-05-22, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT02860923 at 2026-07-30T16:19:36.924Z. Its registry update date was 2026-05-22, and PeptideScanner's reviewed identity mapping was exenatide.
PubMed lists PMID 39406508 in Pharmacological reviews as Journal Article, Review, with publication-date metadata of 2024-10-16 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT06373731 at 2026-07-30T16:19:36.914Z. Its registry update date was 2026-05-20, and PeptideScanner's reviewed identity mapping was elamipretide.
PubMed lists PMID 38619705 in Drug delivery and translational research as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-04-15 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained PubMed bibliographic metadata for PMID 41240216 at 2026-07-30T16:20:41.667Z. PubMed recorded a metadata revision date of 2026-05-20 and an Entrez history date of 2025-11-15. PeptideScanner associated this retained record with the identity slug epitalon. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 39289684 at 2026-07-30T16:20:39.015Z. PubMed recorded a metadata revision date of 2026-05-19 and an Entrez history date of 2024-09-17. PeptideScanner associated this retained record with the identity slug vosoritide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 39574155 at 2026-07-30T16:20:39.074Z. PubMed recorded a metadata revision date of 2026-05-19 and an Entrez history date of 2024-11-22. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT04469855 at 2026-07-30T16:19:36.922Z. Its registry update date was 2026-05-19, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01293292 at 2026-07-30T16:19:36.921Z. Its registry update date was 2026-05-19, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT06554717 at 2026-07-30T16:19:36.918Z. Its registry update date was 2026-05-19, and PeptideScanner's reviewed identity mapping was tesamorelin.
PubMed lists PMID 19461505 in AIDS (London, England) as Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2009-07-17 (day precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 23343061 in The New England journal of medicine as Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, and 1 more PubMed publication type, with publication-date metadata of 2013-01-24 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 23343062 in The New England journal of medicine as Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2013-01-24 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 23424159 in Annals of neurology as Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, with publication-date metadata of 2013-03-11 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 40993014 in Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria as Systematic Review, Journal Article, with publication-date metadata of 2025-09-23 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 18772447 in Stroke as Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, with publication-date metadata of 2008-09-04 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 31702883 in The New England journal of medicine as Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, and 1 more PubMed publication type, with publication-date metadata of 2019-11-08 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 33657294 in The New England journal of medicine as Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-03-04 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 36780675 in The New England journal of medicine as Randomized Controlled Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-02-09 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 39081745 in Kidney international reports as Journal Article, with publication-date metadata of 2024-04-04 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 26044820 in BMC musculoskeletal disorders as Journal Article, Multicenter Study, Observational Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2015-06-05 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 31034184 in The New England journal of medicine as Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-04-28 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained PubMed bibliographic metadata for PMID 33137293 at 2026-07-30T16:20:34.542Z. PubMed recorded a metadata revision date of 2026-05-18 and an Entrez history date of 2020-11-02. PeptideScanner associated this retained record with the identity slug setmelanotide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 37268435 at 2026-07-30T16:20:36.524Z. PubMed recorded a metadata revision date of 2026-05-18 and an Entrez history date of 2023-06-02. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 38071418 at 2026-07-30T16:20:36.586Z. PubMed recorded a metadata revision date of 2026-05-18 and an Entrez history date of 2023-12-10. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 39244617 at 2026-07-30T16:20:38.998Z. PubMed recorded a metadata revision date of 2026-05-18 and an Entrez history date of 2024-09-07. PeptideScanner associated this retained record with the identity slug ziconotide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 39605874 at 2026-07-30T16:20:39.082Z. PubMed recorded a metadata revision date of 2026-05-18 and an Entrez history date of 2024-11-28. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 22564709 at 2026-07-30T16:20:34.419Z. PubMed recorded a metadata revision date of 2026-05-18 and an Entrez history date of 2012-05-09. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 25331030 at 2026-07-30T16:20:34.456Z. PubMed recorded a metadata revision date of 2026-05-18 and an Entrez history date of 2014-10-22. PeptideScanner associated this retained record with the identity slug ipamorelin. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT05989711 at 2026-07-30T16:19:36.923Z. Its registry update date was 2026-05-18, and PeptideScanner's reviewed identity mapping was pemvidutide.
PeptideScanner retained ClinicalTrials.gov record NCT06041217 at 2026-07-30T16:19:36.910Z. Its registry update date was 2026-05-18, and PeptideScanner's reviewed identity mapping was semaglutide.
PubMed lists PMID 39491674 in Journal of pharmaceutical sciences as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-11-02 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 42136855 in Frontiers in medicine as Journal Article, Review, with publication-date metadata of 2026-04-29 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained PubMed bibliographic metadata for PMID 38159221 at 2026-07-30T16:20:36.597Z. PubMed recorded a metadata revision date of 2026-05-15 and an Entrez history date of 2023-12-30. PeptideScanner associated this retained record with the identity slug linaclotide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 42123221 at 2026-07-30T16:20:45.661Z. PubMed recorded a metadata revision date of 2026-05-15 and an Entrez history date of 2026-05-13. PeptideScanner associated this retained record with the identity slug bpc-157. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT00544830 at 2026-07-30T16:19:36.909Z. Its registry update date was 2026-05-15, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT07557953 at 2026-07-30T16:19:36.906Z. Its registry update date was 2026-05-15, and PeptideScanner's reviewed identity mapping was cagrilintide.
PeptideScanner retained ClinicalTrials.gov record NCT05652205 at 2026-07-30T16:19:36.913Z. Its registry update date was 2026-05-14, and PeptideScanner's reviewed identity mapping was linaclotide.
PeptideScanner retained ClinicalTrials.gov record NCT05151484 at 2026-07-30T16:19:36.911Z. Its registry update date was 2026-05-14, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT07523633 at 2026-07-30T16:19:36.919Z. Its registry update date was 2026-05-14, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT03770338 at 2026-07-30T16:19:36.903Z. Its registry update date was 2026-05-14, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT07379333 at 2026-11-16T17:34:46.889Z. Its registry update date was 2026-05-13, and PeptideScanner's reviewed identity mapping was efpeglenatide.
PubMed lists PMID 18629384 in The Canadian journal of cardiology as Journal Article, Review, with publication-date metadata of 2008-07 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 42126578 in Psychopharmacology as Journal Article, Review, with publication-date metadata of 2026-05-13 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
FDA's dated enforcement report D-0519-2026 lists Class II and source status Ongoing for Teva Pharmaceuticals USA, Inc. PeptideScanner connects the report to reviewed application ANDA210317 through exact openFDA application-number annotations.
DailyMed lists Structured Product Labeling version 11 for the reviewed Afamelanotide label family with a published date of 2026-05-13. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained PubMed bibliographic metadata for PMID 38871561 at 2026-07-30T16:20:38.896Z. PubMed recorded a metadata revision date of 2026-05-13 and an Entrez history date of 2024-06-13. PeptideScanner associated this retained record with the identity slug dulaglutide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT03934684 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-05-11, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT04427241 at 2026-11-16T17:33:14.861Z. Its registry update date was 2026-05-11, and PeptideScanner's reviewed identity mapping was cerebrolysin.
DailyMed lists Structured Product Labeling version 19 for the reviewed Leuprolide label family with a published date of 2026-05-11. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT01155232 at 2026-07-30T16:19:36.922Z. Its registry update date was 2026-05-11, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT05586802 at 2026-07-30T16:19:36.909Z. Its registry update date was 2026-05-11, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07059377 at 2026-07-30T16:19:36.906Z. Its registry update date was 2026-05-11, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT05959252 at 2026-11-15T21:58:19.888Z. Its registry update date was 2026-05-08, and PeptideScanner's reviewed identity mapping was bivalirudin.
PeptideScanner retained ClinicalTrials.gov record NCT06734273 at 2026-07-30T16:19:36.910Z. Its registry update date was 2026-05-08, and PeptideScanner's reviewed identity mapping was tirzepatide.
PubMed lists PMID 38084653 in Perfusion as Journal Article, Review, with publication-date metadata of 2023-12-12 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained PubMed bibliographic metadata for PMID 38719260 at 2026-07-30T16:20:36.695Z. PubMed recorded a metadata revision date of 2026-05-07 and an Entrez history date of 2024-05-08. PeptideScanner associated this retained record with the identity slug dulaglutide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT05137119 at 2026-11-15T22:01:45.056Z. Its registry update date was 2026-05-06, and PeptideScanner's reviewed identity mapping was daptomycin.
The official Drugs@FDA dataset lists original submission 1 for ANDA 212068 with status AP dated 2026-05-06, and names vasopressin among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 212069 with status AP dated 2026-05-06, and names vasopressin among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT04575844 at 2026-07-30T16:19:36.923Z. Its registry update date was 2026-05-06, and PeptideScanner's reviewed identity mapping was liraglutide.
DailyMed lists Structured Product Labeling version 38 for the reviewed Tirzepatide label family with a published date of 2026-05-06. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT07298915 at 2026-07-30T16:19:36.919Z. Its registry update date was 2026-05-06, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained PubMed bibliographic metadata for PMID 42083939 at 2026-07-30T16:20:43.803Z. PubMed recorded a metadata revision date of 2026-05-05 and an Entrez history date of 2026-05-05. PeptideScanner associated this retained record with the identity slug dulaglutide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 40536052 at 2026-07-30T16:20:41.387Z. PubMed recorded a metadata revision date of 2026-05-04 and an Entrez history date of 2025-06-19. PeptideScanner associated this retained record with the identity slug dulaglutide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT04019197 at 2026-07-30T16:19:36.918Z. Its registry update date was 2026-05-04, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07443956 at 2026-07-30T16:19:36.909Z. Its registry update date was 2026-05-04, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07554638 at 2026-07-30T16:19:36.907Z. Its registry update date was 2026-05-04, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained PubMed bibliographic metadata for PMID 42068058 at 2026-07-30T16:20:43.725Z. PubMed recorded a metadata revision date of 2026-05-02 and an Entrez history date of 2026-05-02. PeptideScanner associated this retained record with the identity slug setmelanotide. These dates describe PubMed metadata history, not the article's original publication date.
PubMed lists PMID 41314023 in Journal of the neurological sciences as Journal Article, Multicenter Study, Observational Study, with publication-date metadata of 2025-11-24 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
The Federal Register published notice 2026-08552, attributed to FDA and its parent HHS department, on 2026-05-01. Its official title is “List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon, Liraglutide, Semaglutide and Tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT04194554 at 2026-07-30T16:19:36.919Z. Its registry update date was 2026-05-01, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT02944500 at 2026-07-30T16:19:36.903Z. Its registry update date was 2026-05-01, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT03856632 at 2026-07-30T16:19:36.910Z. Its registry update date was 2026-05-01, and PeptideScanner's reviewed identity mapping was liraglutide.
PubMed lists PMID 40154876 in Resuscitation as Journal Article, Randomized Controlled Trial, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-03-26 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
The Federal Register published notice 2026-08435, attributed to FDA and its parent HHS department, on 2026-04-30. Its official title is “Determination That OZEMPIC (Semaglutide) Solution, 2 Milligrams Per 1.5 Milliliters Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide.
PubMed lists PMID 38206830 in The oncologist as Journal Article, Clinical Trial, Phase II, Research Support, Non-U.S. Gov't, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2024-05-03 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT06176365 at 2026-07-30T16:20:49.317Z. Its registry update date was 2026-04-30, and PeptideScanner's reviewed identity mapping was survodutide.
PeptideScanner retained ClinicalTrials.gov record NCT06309992 at 2026-07-30T16:20:49.307Z. Its registry update date was 2026-04-30, and PeptideScanner's reviewed identity mapping was survodutide.
FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the list of bulk substances that 503B outsourcing facilities may use for compounding.
PeptideScanner retained ClinicalTrials.gov record NCT07495722 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-04-29, and PeptideScanner's reviewed identity mapping was pegcetacoplan.
PeptideScanner retained ClinicalTrials.gov record NCT07304466 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-04-29, and PeptideScanner's reviewed identity mapping was terlipressin.
The official Drugs@FDA dataset lists original submission 1 for ANDA 218740 with status AP dated 2026-04-29, and names cetrorelix acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for BLA 761412 with status AP dated 2026-04-29, and names insulin glargine-aldy among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT04174755 at 2026-07-30T16:20:49.311Z. Its registry update date was 2026-04-29, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT05500586 at 2026-07-30T16:20:49.307Z. Its registry update date was 2026-04-29, and PeptideScanner's reviewed identity mapping was glucagon.
PeptideScanner retained ClinicalTrials.gov record NCT03841058 at 2026-07-30T16:20:49.320Z. Its registry update date was 2026-04-28, and PeptideScanner's reviewed identity mapping was abaloparatide.
PeptideScanner retained ClinicalTrials.gov record NCT07065552 at 2026-07-30T16:20:49.313Z. Its registry update date was 2026-04-28, and PeptideScanner's reviewed identity mapping was tirzepatide.
PubMed lists PMID 23805635 in Vestnik Rossiiskoi akademii meditsinskikh nauk as Journal Article, Review, with publication-date metadata of 2013 (year precision). PeptideScanner associated the retained record with the identity slug cerebrolysin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 41258966 in Hepatology international as Letter, Comment, with publication-date metadata of 2025-11-19 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 41776028 in Hepatology international as Editorial, with publication-date metadata of 2026-03-03 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained PubMed bibliographic metadata for PMID 41959165 at 2026-07-30T16:22:18.487Z. PubMed recorded a metadata revision date of 2026-04-27 and an Entrez history date of 2026-04-10. PeptideScanner associated this retained record with the identity slug setmelanotide. These dates describe PubMed metadata history, not the article's original publication date.
PubMed lists PMID 42028934 in Medecine sciences : M/S as Journal Article, with publication-date metadata of 2026-04-24 (day precision). PeptideScanner associated the retained record with the identity slug humanin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT05982093 at 2026-11-15T21:49:16.513Z. Its registry update date was 2026-04-24, and PeptideScanner's reviewed identity mapping was triptorelin.
PeptideScanner retained PubMed bibliographic metadata for PMID 41960633 at 2026-07-30T16:22:18.490Z. PubMed recorded a metadata revision date of 2026-04-24 and an Entrez history date of 2026-04-10. PeptideScanner associated this retained record with the identity slug bremelanotide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT04961528 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-04-23, and PeptideScanner's reviewed identity mapping was terlipressin.
PeptideScanner retained ClinicalTrials.gov record NCT05646706 at 2026-07-30T16:20:49.307Z. Its registry update date was 2026-04-23, and PeptideScanner's reviewed identity mapping was semaglutide.
The Federal Register published rule 2026-07863, attributed to FDA and its parent HHS department, on 2026-04-22. Its official title is “Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Setmelanotide Eligibility Gene Variant Detection System,” and PeptideScanner's exact reviewed identity mapping connects the document to Setmelanotide.
PeptideScanner retained ClinicalTrials.gov record NCT06283667 at 2026-07-30T16:20:49.310Z. Its registry update date was 2026-04-22, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01816971 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-04-21, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT04572854 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-04-21, and PeptideScanner's reviewed identity mapping was pegcetacoplan.
PeptideScanner retained ClinicalTrials.gov record NCT04428008 at 2026-11-15T22:10:40.222Z. Its registry update date was 2026-04-21, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.
PeptideScanner retained ClinicalTrials.gov record NCT06124807 at 2026-07-30T16:20:49.321Z. Its registry update date was 2026-04-21, and PeptideScanner's reviewed identity mapping was mazdutide.
PeptideScanner retained PubMed bibliographic metadata for PMID 41157964 at 2026-07-30T16:22:16.190Z. PubMed recorded a metadata revision date of 2026-04-21 and an Entrez history date of 2025-10-29. PeptideScanner associated this retained record with the identity slug vosoritide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT05746039 at 2026-07-30T16:20:49.311Z. Its registry update date was 2026-04-21, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06424106 at 2026-07-30T16:20:49.305Z. Its registry update date was 2026-04-20, and PeptideScanner's reviewed identity mapping was glucagon.
PeptideScanner retained ClinicalTrials.gov record NCT06657209 at 2026-07-30T16:20:49.310Z. Its registry update date was 2026-04-20, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT05482789 at 2026-07-30T16:20:49.324Z. Its registry update date was 2026-04-20, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained PubMed bibliographic metadata for PMID 38987029 at 2026-07-30T16:22:12.162Z. PubMed recorded a metadata revision date of 2026-04-17 and an Entrez history date of 2024-07-10. PeptideScanner associated this retained record with the identity slug setmelanotide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 39284294 at 2026-07-30T16:22:15.952Z. PubMed recorded a metadata revision date of 2026-04-17 and an Entrez history date of 2024-09-16. PeptideScanner associated this retained record with the identity slug setmelanotide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 41401696 at 2026-07-30T16:22:18.312Z. PubMed recorded a metadata revision date of 2026-04-17 and an Entrez history date of 2025-12-16. PeptideScanner associated this retained record with the identity slug setmelanotide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 41994885 at 2026-07-30T16:22:19.404Z. PubMed recorded a metadata revision date of 2026-04-17 and an Entrez history date of 2026-04-17. PeptideScanner associated this retained record with the identity slug setmelanotide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT06558188 at 2026-07-30T16:20:49.311Z. Its registry update date was 2026-04-17, and PeptideScanner's reviewed identity mapping was teriparatide.
PubMed lists PMID 38540740 in Biomolecules as Journal Article, Review, Research Support, N.I.H., Extramural, with publication-date metadata of 2024-03-08 (day precision). PeptideScanner associated the retained record with the identity slug ll-37. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
The Federal Register published notice 2026-07361, attributed to FDA and its parent HHS department, on 2026-04-16. Its official title is “Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List,” and PeptideScanner's exact reviewed identity mapping connects the document to BPC-157, Emideltide, Epitalon, KPV, MOTS-c, Semax and TB-500.
PeptideScanner retained ClinicalTrials.gov record NCT05951400 at 2026-11-15T22:02:39.332Z. Its registry update date was 2026-04-15, and PeptideScanner's reviewed identity mapping was cetrorelix.
FDA's dated enforcement report D-0422-2026 lists Class II and source status Ongoing for Cipla USA, Inc. PeptideScanner connects the report to reviewed application NDA215395 through exact openFDA application-number annotations.
FDA's dated enforcement report D-0423-2026 lists Class II and source status Ongoing for Cipla USA, Inc. PeptideScanner connects the report to reviewed application ANDA217193 through exact openFDA application-number annotations.
PeptideScanner retained ClinicalTrials.gov record NCT06811324 at 2026-07-30T16:20:49.320Z. Its registry update date was 2026-04-15, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT06256432 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-04-13, and PeptideScanner's reviewed identity mapping was terlipressin.
PeptideScanner retained ClinicalTrials.gov record NCT07411560 at 2026-07-30T16:20:49.304Z. Its registry update date was 2026-04-13, and PeptideScanner's reviewed identity mapping was cagrilintide.
PeptideScanner retained ClinicalTrials.gov record NCT02772588 at 2026-07-30T16:20:49.312Z. Its registry update date was 2026-04-13, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT02960022 at 2026-07-30T16:20:49.311Z. Its registry update date was 2026-04-13, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT06751589 at 2026-07-30T16:20:49.318Z. Its registry update date was 2026-04-13, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained PubMed bibliographic metadata for PMID 41967490 at 2026-07-30T16:22:18.495Z. PubMed recorded a metadata revision date of 2026-04-12 and an Entrez history date of 2026-04-12. PeptideScanner associated this retained record with the identity slug vosoritide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 41123247 at 2026-07-30T16:22:16.181Z. PubMed recorded a metadata revision date of 2026-04-10 and an Entrez history date of 2025-10-22. PeptideScanner associated this retained record with the identity slug linaclotide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT05738148 at 2026-11-15T22:08:31.832Z. Its registry update date was 2026-04-09, and PeptideScanner's reviewed identity mapping was vasopressin.
PeptideScanner retained ClinicalTrials.gov record NCT05048901 at 2026-07-30T16:20:49.324Z. Its registry update date was 2026-04-09, and PeptideScanner's reviewed identity mapping was lanreotide.
PeptideScanner retained ClinicalTrials.gov record NCT02127437 at 2026-07-30T16:20:49.305Z. Its registry update date was 2026-04-08, and PeptideScanner's reviewed identity mapping was lanreotide.
PeptideScanner retained ClinicalTrials.gov record NCT07338214 at 2026-07-30T16:20:49.304Z. Its registry update date was 2026-04-08, and PeptideScanner's reviewed identity mapping was petrelintide.
PeptideScanner retained ClinicalTrials.gov record NCT00302822 at 2026-11-16T01:41:15.051Z. Its registry update date was 2026-04-07, and PeptideScanner's reviewed identity mapping was enfuvirtide.
PeptideScanner retained ClinicalTrials.gov record NCT07104383 at 2026-11-16T17:46:36.579Z. Its registry update date was 2026-04-07, and PeptideScanner's reviewed identity mapping was vk2735.
PeptideScanner retained PubMed bibliographic metadata for PMID 34006921 at 2026-07-30T16:22:11.959Z. PubMed recorded a metadata revision date of 2026-04-07 and an Entrez history date of 2021-05-19. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT04983901 at 2026-11-15T22:01:45.056Z. Its registry update date was 2026-04-06, and PeptideScanner's reviewed identity mapping was daptomycin.
PeptideScanner retained ClinicalTrials.gov record NCT06275555 at 2026-11-15T21:58:19.888Z. Its registry update date was 2026-04-06, and PeptideScanner's reviewed identity mapping was bivalirudin.
PeptideScanner retained PubMed bibliographic metadata for PMID 33858329 at 2026-07-30T16:22:11.958Z. PubMed recorded a metadata revision date of 2026-04-06 and an Entrez history date of 2021-04-16. PeptideScanner associated this retained record with the identity slug linaclotide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT06604624 at 2026-07-30T16:20:49.309Z. Its registry update date was 2026-04-06, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained PubMed bibliographic metadata for PMID 41615893 at 2026-07-30T16:22:18.348Z. PubMed recorded a metadata revision date of 2026-04-04 and an Entrez history date of 2026-01-30. PeptideScanner associated this retained record with the identity slug vosoritide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT01813227 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-04-03, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT02892942 at 2026-11-15T22:02:39.332Z. Its registry update date was 2026-04-03, and PeptideScanner's reviewed identity mapping was cetrorelix.
PeptideScanner retained ClinicalTrials.gov record NCT03119584 at 2026-07-30T16:20:49.311Z. Its registry update date was 2026-04-03, and PeptideScanner's reviewed identity mapping was linaclotide.
PeptideScanner retained ClinicalTrials.gov record NCT00120367 at 2026-11-16T01:41:15.051Z. Its registry update date was 2026-04-02, and PeptideScanner's reviewed identity mapping was enfuvirtide.
PeptideScanner retained ClinicalTrials.gov record NCT05809531 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-04-02, and PeptideScanner's reviewed identity mapping was pegcetacoplan.
DailyMed lists Structured Product Labeling version 17 for the reviewed Semaglutide label family with a published date of 2026-04-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 14 for the reviewed Setmelanotide label family with a published date of 2026-04-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for NDA 220934 with status AP dated 2026-04-01, and names orforglipron calcium among the application record's active ingredients.
FDA's dated enforcement report D-0404-2026 lists Class II and source status Ongoing for Teva Pharmaceuticals USA, Inc. PeptideScanner connects the report to reviewed application ANDA210317 through exact openFDA application-number annotations.
FDA's dated enforcement report D-0405-2026 lists Class II and source status Ongoing for Teva Pharmaceuticals USA, Inc. PeptideScanner connects the report to reviewed application ANDA210317 through exact openFDA application-number annotations.
FDA's dated enforcement report D-0406-2026 lists Class II and source status Ongoing for Teva Pharmaceuticals USA, Inc. PeptideScanner connects the report to reviewed application ANDA210317 through exact openFDA application-number annotations.
PeptideScanner retained PubMed bibliographic metadata for PMID 38905488 at 2026-07-30T16:22:12.148Z. PubMed recorded a metadata revision date of 2026-04-01 and an Entrez history date of 2024-06-21. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT06264609 at 2026-07-30T16:20:49.326Z. Its registry update date was 2026-04-01, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT06734130 at 2026-07-30T16:20:49.318Z. Its registry update date was 2026-04-01, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT04040088 at 2026-11-16T17:36:42.191Z. Its registry update date was 2026-03-31, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate.
PeptideScanner retained ClinicalTrials.gov record NCT04069299 at 2026-11-16T17:36:42.191Z. Its registry update date was 2026-03-31, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate.
PeptideScanner retained ClinicalTrials.gov record NCT07126262 at 2026-07-30T16:22:22.346Z. Its registry update date was 2026-03-31, and PeptideScanner's reviewed identity mapping was vosoritide.
PeptideScanner retained ClinicalTrials.gov record NCT06807437 at 2026-07-30T16:22:22.334Z. Its registry update date was 2026-03-31, and PeptideScanner's reviewed identity mapping was lanreotide.